Twist Bioscience Corporation
TWST
Rang in aandelen
#2144
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Aandeelprijs
$144.87
Marktkapitalisatie
$9.54B
Verandering (1 dag)
3.65%
Verandering (1 jaar)
342.47%
Land
US
Handel Twist Bioscience Corporation (TWST)
Categorie
Healthcare
Winst voor Twist Bioscience Corporation (TWST)
Winst in Jun 2026 TTM: $-135.85M
Volgens de meest recente financiële verslagen van Twist Bioscience Corporation bedraagt de huidige winst van het bedrijf $-135.85M. In 2024 behaalde het bedrijf een winst van $-208.17M, een daling ten opzichte van de winst van 2023, die $-203.47M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Twist Bioscience Corporation van 2016 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-135.85M | 76.55% |
| 2025 | $-76.95M | -63.03% |
| 2024 | $-208.17M | 2.31% |
| 2023 | $-203.47M | -10.87% |
| 2022 | $-228.27M | 48.20% |
| 2021 | $-154.03M | 10.38% |
| 2020 | $-139.55M | 29.96% |
| 2019 | $-107.38M | 51.25% |
| 2018 | $-70.99M | 20.27% |
| 2017 | $-59.03M | 33.89% |
| 2016 | $-44.09M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $7.61B | -5,700.87% |
US
|
|
| $4.76B | -3,605.23% |
US
|
|
| $-252.70M | 86.01% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -1,320.43% |
US
|
